Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) EPS (Basic): 2010-2025

Historic EPS (Basic) for Heron Therapeutics (HRTX) over the last 13 years, with Sep 2025 value amounting to -$0.10.

  • Heron Therapeutics' EPS (Basic) fell 233.33% to -$0.10 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.08, marking a year-over-year increase of 50.00%. This contributed to the annual value of -$0.09 for FY2024, which is 88.75% up from last year.
  • According to the latest figures from Q3 2025, Heron Therapeutics' EPS (Basic) is -$0.10, which was down 400.00% from -$0.02 recorded in Q2 2025.
  • Heron Therapeutics' EPS (Basic)'s 5-year high stood at $0.02 during Q4 2024, with a 5-year trough of -$0.63 in Q1 2022.
  • In the last 3 years, Heron Therapeutics' EPS (Basic) had a median value of -$0.05 in 2023 and averaged -$0.09.
  • Over the last 5 years, Heron Therapeutics' EPS (Basic) had its largest YoY gain of 200.00% in 2025, and its largest YoY loss of 233.33% in 2025.
  • Quarterly analysis of 5 years shows Heron Therapeutics' EPS (Basic) stood at -$0.53 in 2021, then spiked by 75.47% to -$0.13 in 2022, then skyrocketed by 61.54% to -$0.05 in 2023, then spiked by 140.00% to $0.02 in 2024, then plummeted by 233.33% to -$0.10 in 2025.
  • Its last three reported values are -$0.10 in Q3 2025, -$0.02 for Q2 2025, and $0.02 during Q1 2025.